KalVista Presents New Data at Global Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy KALV?
Source: Newsfilter
- Clinical Trial Progress: KalVista Pharmaceuticals announced that interim data from its KONFIDENT-KID trial has been accepted for oral presentation at the 2026 Global Angioedema Leadership Conference, highlighting the company's ongoing commitment to treating hereditary angioedema in children.
- Conference Presentation Schedule: The conference will take place from March 26-29, 2026, in Madrid, Spain, featuring a significant oral presentation that is expected to attract widespread attention within the industry, thereby enhancing KalVista's market visibility.
- Potential of EKTERLY®: EKTERLY (sebetralstat), as the first oral on-demand treatment for hereditary angioedema, is anticipated to seek expansion for use in children aged 2-11 in 2026, potentially establishing itself as a foundational therapy for HAE management worldwide.
- Global Market Expansion Plans: KalVista plans regulatory filings in multiple key markets, demonstrating its commitment to addressing unmet medical needs and solidifying its leadership position in the rare disease treatment sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.490
Low
29.00
Averages
34.38
High
39.00
Current: 15.490
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KalVista Presents New Data at Global Conference
- Clinical Trial Progress: KalVista Pharmaceuticals announced that interim data from its KONFIDENT-KID trial has been accepted for oral presentation at the 2026 Global Angioedema Leadership Conference, highlighting the company's ongoing commitment to treating hereditary angioedema in children.
- Conference Presentation Schedule: The conference will take place from March 26-29, 2026, in Madrid, Spain, featuring a significant oral presentation that is expected to attract widespread attention within the industry, thereby enhancing KalVista's market visibility.
- Potential of EKTERLY®: EKTERLY (sebetralstat), as the first oral on-demand treatment for hereditary angioedema, is anticipated to seek expansion for use in children aged 2-11 in 2026, potentially establishing itself as a foundational therapy for HAE management worldwide.
- Global Market Expansion Plans: KalVista plans regulatory filings in multiple key markets, demonstrating its commitment to addressing unmet medical needs and solidifying its leadership position in the rare disease treatment sector.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
KalVista Pharmaceuticals to Host Financial Results Conference Call
- Conference Call Announcement: KalVista Pharmaceuticals will host a conference call on March 25, 2026, at 8:30 a.m. ET to review its eight-month fiscal year 2025 financial results and provide a corporate update, aiming to enhance investor understanding of the company's financial health.
- Webcast Accessibility: The live audio webcast will be accessible on the Investors section of the company's website, ensuring that global investors can receive real-time information, thereby increasing transparency and boosting market confidence.
- Product Innovation Context: KalVista is dedicated to delivering life-changing therapies for rare disease patients, with EKTERLY® being the first and only oral on-demand treatment for hereditary angioedema, showcasing the company's innovative capabilities and market potential in this niche area.
- Global Community Collaboration: KalVista works closely with the global hereditary angioedema community to improve treatment and care for this disease, reflecting the company's commitment to addressing patient needs and fulfilling its social responsibility.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
KalVista Presents New Data at Global Conference
- Clinical Trial Progress: KalVista Pharmaceuticals announced that interim data from its KONFIDENT-KID trial has been accepted for oral presentation at the 2026 Global Angioedema Leadership Conference, highlighting the company's ongoing commitment to treating hereditary angioedema in children.
- Conference Presentation Schedule: The conference will take place from March 26-29, 2026, in Madrid, Spain, featuring a significant oral presentation that is expected to attract widespread attention within the industry, thereby enhancing KalVista's market visibility.
- Potential of EKTERLY®: EKTERLY (sebetralstat), as the first oral on-demand treatment for hereditary angioedema, is anticipated to seek expansion for use in children aged 2-11 in 2026, potentially establishing itself as a foundational therapy for HAE management worldwide.
- Global Market Expansion Plans: KalVista plans regulatory filings in multiple key markets, demonstrating its commitment to addressing unmet medical needs and solidifying its leadership position in the rare disease treatment sector.
See More
VR Adviser, LLC Reduces Stake in Ocular Therapeutix
- Share Reduction Details: On February 17, 2026, VR Adviser, LLC disclosed the sale of 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $70.96 million, indicating a potential decline in confidence in the stock.
- Asset Management Impact: This transaction reduced Ocular Therapeutix's share of VR Adviser's reportable assets under management to 4.39%, with a holding value of $88.81 million, reflecting a diminished significance in the fund's portfolio.
- Market Performance Analysis: As of February 17, 2026, Ocular Therapeutix shares were priced at $6.99, down 3.98% over the past year, underperforming the S&P 500 by 15.90 percentage points, suggesting low market expectations for future growth.
- Investor Considerations: While the reduction is a routine portfolio management action, Ocular Therapeutix's product DEXTENZA and its drug delivery technology offer differentiation in a competitive ophthalmology market, warranting investor attention on its future market expansion and revenue growth potential.
See More
VR Adviser, LLC Sells Shares of Ocular Therapeutix
- Share Sale Overview: On February 17, 2026, VR Adviser, LLC disclosed to the SEC that it sold 5,845,915 shares of Ocular Therapeutix, with an estimated transaction value of $71.01 million, reducing its stake in the company to 4.4%.
- Asset Management Impact: The sale resulted in a $65.05 million decrease in the value of VR Adviser's position, highlighting the direct impact of trading and stock price fluctuations on its assets under management during the fourth quarter.
- Portfolio Adjustment: This transaction represented 3.51% of VR Adviser's reportable assets under management, indicating routine portfolio management adjustments within its strategy of concentrated investments in small-cap biotech firms.
- Market Performance Analysis: Ocular Therapeutix's stock has declined approximately 4% over the past year and has underperformed the S&P 500 by about 16 points, reflecting uneven growth in a competitive ophthalmic pharmaceutical market, which may affect investor confidence.
See More
KalVista Pharmaceuticals to Host Financial Results Conference Call
- Conference Call Announcement: KalVista Pharmaceuticals will host a conference call on March 25, 2026, at 8:30 a.m. ET to review its eight-month fiscal year 2025 financial results and provide a corporate update, aiming to enhance investor understanding of the company's financial health.
- Webcast Accessibility: The live audio webcast will be accessible on the Investors section of the company's website, ensuring that global investors can receive real-time information, thereby increasing transparency and boosting market confidence.
- Product Innovation Context: KalVista is dedicated to delivering life-changing therapies for rare disease patients, with EKTERLY® being the first and only oral on-demand treatment for hereditary angioedema, showcasing the company's innovative capabilities and market potential in this niche area.
- Global Community Collaboration: KalVista works closely with the global hereditary angioedema community to improve treatment and care for this disease, reflecting the company's commitment to addressing patient needs and fulfilling its social responsibility.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
